Cosmos Health Inc. (COSM) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Cosmos Health Inc. is an international healthcare group operating in the nutraceutical, pharmaceutical, and healthcare distribution sectors. The company is headquartered in Chicago with significant operations in Greece and the UK. It is classified as a Smaller Reporting Company and trades on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $13,206,717 | $27,791,190 | $24,713,206 |
| Gross Profit | $767,248 | $2,100,874 | $1,903,911 |
| Gross Margin | 5.8% | 7.6% | 7.7% |
| Net Loss | $(2,590,711) | $(4,457,401) | $(1,441,393) |
| Net Loss Per Share (Basic/Diluted) | $(0.15) | $(0.26) | $(0.13) |
| Cash and Equivalents | $343,509 | $343,509 | $2,232,697 |
| Working Capital | $8,593,711 | $8,593,711 | $12,285,310 |
| Total Debt (Notes & Lines of Credit) | $11,041,375 | $11,041,375 | $11,236,496 |
Note: Total Debt includes Lines of Credit ($7.1M) and Notes Payable ($3.9M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6.8% quarter-over-quarter and 12.5% year-over-year (YTD), driven by wholesale volume and the integration of the Cana acquisition.
- Margin Compression: Gross profit decreased 19% in Q2 2024 compared to Q2 2023. This is attributed to a shift in sales mix toward lower-margin wholesale products and decreased sales of high-margin nutraceuticals and pharma manufacturing.
- Increased Net Loss: The YTD net loss widened significantly compared to 2023. The 2023 period included non-recurring gains of $1.9M (debt extinguishment) and $1.6M (bargain purchase gain from Cana acquisition) which were absent in 2024.
- Cash Position: Cash and cash equivalents dropped from $3.8M at year-end 2023 to $343k at June 30, 2024, due to operating cash outflows and capital expenditures.
- Interest Expense: Interest expense rose 35% YTD due to increased floating interest rates (Euribor/LIBOR) on lines of credit and notes payable.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months. This is due to recurring net losses, negative operating cash flows, and an accumulated deficit of $96.1M.
- Liquidity Strategy: Plans to address liquidity include raising additional equity via warrant exercises, securing debt financing through subsidiaries, and potentially postponing repayments on trade facilities and supplier obligations.
- Strategic Initiatives: The company is focusing on vertical integration, expanding the "Sky Premium Life" nutraceutical brand globally (including a new UAE distribution deal), and utilizing Cana's manufacturing capabilities for contract manufacturing.
- Controls and Procedures: The company disclosed that its disclosure controls and procedures were ineffective due to material weaknesses, specifically a lack of segregation of duties and insufficient IT General Controls. Remediation is planned for completion by December 31, 2024.
- Legal Proceedings: Several pending litigations exist, including tax audits and customer disputes, though management does not expect them to have a material financial impact.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the drop in cash to $343k and the explicit "Going Concern" warning.
- Related Party Transactions: Review the significant balances with Doc Pharma (related party), including $5.7M in prepaid expenses and $2.7M in receivables, to assess dependency and valuation risks.
- Debt Covenants: Confirm compliance with financial ratios on lines of credit, particularly given the liquidity constraints.
- Internal Controls: Assess the timeline and progress of remediation for the material weaknesses in internal controls over financial reporting.
- Revenue Quality: Analyze the concentration of revenue in Greece (approx. 97% of YTD revenue) and the collectability of receivables from key distributors like Medihelm SA.